Lixte Biotechnology Hldgs Inc Financials
This page shows Lixte Biotechnology Hldgs Inc (LIXT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Lixte’s operating model is still capital-raise funded, and FY2025 spending tilted further from research toward overhead.
FY2025 shows a widening gap between net loss and operating cash burn: the company reported$6.1M of loss but used only-$3.1M of operating cash. Cash ended the year at$5.1M only after$10.3M of financing inflow, so liquidity improved even though the underlying operating model still did not fund itself.
The cost structure changed materially: R&D fell to
The balance sheet looks lightly levered on paper, with debt-to-equity of 0.2x and a current ratio near 3.9x in FY2025, which limits near-term pressure from creditors. But the share count expanded to 8.8M from 2.2M, showing that this cushion was rebuilt mainly through equity issuance rather than through internally generated cash.
Financial Health Signals
Lixte Biotechnology Hldgs Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Lixte Biotechnology Hldgs Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Lixte Biotechnology Hldgs Inc reported a net loss of $6.1M while operations used $3.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Lixte Biotechnology Hldgs Inc reported an operating loss of $5.1M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Lixte Biotechnology Hldgs Inc reported -$6.1M in net income in fiscal year 2025. This represents a decrease of 69.5% from the prior year.
Lixte Biotechnology Hldgs Inc earned -$1.26 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Lixte Biotechnology Hldgs Inc held $5.1M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Lixte Biotechnology Hldgs Inc's ROE was -62.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 370.6 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Lixte Biotechnology Hldgs Inc invested $255K in research and development in fiscal year 2025. This represents a decrease of 64.9% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
LIXT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $200K | N/A | $0 | $0 | $0 |
| R&D Expenses | N/A | $255K-64.9% | $726K-19.1% | $898K-33.4% | $1.3M-22.3% | $1.7M+41.9% | $1.2M+49.1% | $821K+1916.8% | $41K-91.3% | $467K-46.3% | $870K-58.4% | $2.1M+87.1% | $1.1M+27.1% | $880K-13.1% | $1.0M-24.2% | $1.3M |
| SG&A Expenses | N/A | $4.9M+70.5% | $2.8M-32.1% | $4.2M+64.6% | $2.5M-15.8% | $3.0M+295.3% | $765K-54.2% | $1.7M-20.4% | $2.1M+56.2% | $1.3M+6.1% | $1.3M+67.7% | $754K-41.3% | $1.3M+159.7% | $495K-54.7% | $1.1M+105.0% | $533K |
| Operating Income | N/A | -$5.1M-43.0% | -$3.6M+29.8% | -$5.1M+19.3% | -$6.3M+6.1% | -$6.7M-105.7% | -$3.3M-31.2% | -$2.5M-16.5% | -$2.1M-18.1% | -$1.8M+15.2% | -$2.1M+19.3% | -$2.6M-10.1% | -$2.4M-74.8% | -$1.4M+34.7% | -$2.1M-12.7% | -$1.9M |
| Interest Expense | N/A | $9K-45.6% | $17K+3.6% | $16K+82.9% | $9K+19.7% | $7K+101.8% | $4K | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 |
| Income Tax | N/A | $2K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$6.1M-69.5% | -$3.6M+29.5% | -$5.1M+19.4% | -$6.3M+6.2% | -$6.7M-106.1% | -$3.3M-33.8% | -$2.4M-14.4% | -$2.1M-18.0% | -$1.8M+15.3% | -$2.1M+25.2% | -$2.9M | N/A | -$1.4M+61.6% | -$3.6M-73.1% | -$2.1M |
| EPS (Diluted) | — | -$1.26 | -$1.59+40.2% | -$2.66+33.3% | -$3.99 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
LIXT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $12.7M+1011.6% | $1.1M-73.4% | $4.3M-22.5% | $5.6M+9.2% | $5.1M-2.6% | $5.2M+95.7% | $2.7M-38.4% | $4.3M+217.0% | $1.4M+215.7% | $433K-27.5% | $598K+10.9% | $539K-3.4% | $558K-68.2% | $1.8M+307.9% | $430K |
| Current Assets | $5.2M+352.1% | $1.1M-73.4% | $4.3M-22.5% | $5.6M+9.2% | $5.1M-2.6% | $5.2M+95.7% | $2.7M-38.4% | $4.3M+216.8% | $1.4M+215.7% | $433K-27.5% | $598K+10.9% | $539K-3.4% | $558K-68.2% | $1.8M+307.9% | $430K |
| Cash & Equivalents | $5.1M+391.5% | $1.0M-75.3% | $4.2M-21.5% | $5.4M+11.0% | $4.8M-4.8% | $5.1M+95.1% | $2.6M-39.2% | $4.3M+227.2% | $1.3M+553.1% | $200K+690.8% | $25K-43.1% | $44K-90.7% | $475K-71.3% | $1.7M+11473.5% | $14K |
| Total Liabilities | $1.8M+456.8% | $318K+1.4% | $314K-20.7% | $396K+30.6% | $303K+39.9% | $217K-9.0% | $238K+12.8% | $211K-43.5% | $373K+70.6% | $219K-23.5% | $286K+4.5% | $273K-15.0% | $322K+23.2% | $261K-25.5% | $351K |
| Current Liabilities | $1.3M+318.8% | $318K+1.4% | $314K-20.7% | $396K+30.6% | $303K+39.9% | $217K-9.0% | $238K+12.8% | $211K-43.5% | $373K+70.6% | $219K-23.5% | $286K+4.5% | $273K-15.0% | $322K+23.2% | $261K-25.5% | $351K |
| Total Equity | $9.7M+1068.3% | $827K-79.3% | $4.0M-22.7% | $5.2M+7.8% | $4.8M-4.4% | $5.0M+105.9% | $2.4M-41.0% | $4.1M+314.6% | $995K+363.3% | $215K-31.2% | $312K+17.5% | $266K+12.5% | $236K-84.2% | $1.5M+1787.9% | $79K |
| Retained Earnings | -$58.1M-11.5% | -$52.1M-7.4% | -$48.5M-11.7% | -$43.4M-17.0% | -$37.1M-22.2% | -$30.4M-12.1% | -$27.1M-9.9% | -$24.6M-9.5% | -$22.5M-8.7% | -$20.7M-11.5% | -$18.6M-18.2% | -$15.7M-21.4% | -$13.0M | N/A | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
LIXT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.3M | -$3.1M+3.0% | -$3.2M+26.3% | -$4.3M+6.9% | -$4.6M-11.3% | -$4.1M-94.4% | -$2.1M-227.3% | $1.7M+210.8% | -$1.5M-7.0% | -$1.4M+15.8% | -$1.7M+23.1% | -$2.2M-33.4% | -$1.6M-38.6% | -$1.2M+2.1% | -$1.2M+11.3% | -$1.4M |
| Investing Cash Flow | N/A | -$3.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $104K-5.0% | $110K+152.8% | -$208K-20756300.0% | -$1-100.0% | $345K-72.4% | $1.2M |
| Financing Cash Flow | $10.3M | $10.3M | N/A | $3.1M-38.9% | $5.1M+31.9% | $3.9M-15.3% | $4.6M | N/A | $4.5M+77.9% | $2.5M+44.1% | $1.7M-14.8% | $2.1M+45.3% | $1.4M | $0-100.0% | $2.5M+49931.7% | $5K |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $25K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
LIXT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1323.2% | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1426.0% | N/A | N/A | N/A | N/A |
| Return on Equity | -62.9%+370.6pp | -433.5%-306.2pp | -127.3%-5.1pp | -122.2%+18.3pp | -140.5%-75.3pp | -65.1%+35.1pp | -100.3%-48.6pp | -51.7%+130.0pp | -181.7%+812.3pp | -994.0%-80.8pp | -913.2% | N/A | -581.9%-342.0pp | -239.9%+2377.0pp | -2617.0% |
| Return on Assets | -47.7%+265.3pp | -313.1%-195.0pp | -118.1%-4.6pp | -113.5%+18.6pp | -132.1%-69.7pp | -62.4%+28.9pp | -91.3%-42.1pp | -49.2%+83.0pp | -132.2%+360.3pp | -492.5%-15.6pp | -477.0% | N/A | -246.4%-42.2pp | -204.2%+277.0pp | -481.2% |
| Current Ratio | 3.88+0.3x | 3.60-10.1x | 13.73-0.3x | 14.05-2.8x | 16.81-7.3x | 24.15+12.9x | 11.23-9.3x | 20.55+16.9x | 3.67+1.7x | 1.98-0.1x | 2.09+0.1x | 1.97+0.2x | 1.73-5.0x | 6.71+5.5x | 1.23 |
| Debt-to-Equity | 0.18-0.2x | 0.38+0.3x | 0.080.0x | 0.080.0x | 0.060.0x | 0.04-0.1x | 0.100.0x | 0.05-0.3x | 0.37-0.6x | 1.02+0.1x | 0.91-0.1x | 1.03-0.3x | 1.36+1.2x | 0.18-4.3x | 4.44 |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Where Lixte Biotechnology Hldgs Inc Ranks
Frequently Asked Questions
Is Lixte Biotechnology Hldgs Inc profitable?
No, Lixte Biotechnology Hldgs Inc (LIXT) reported a net income of -$6.1M in fiscal year 2025.
What is Lixte Biotechnology Hldgs Inc's return on equity (ROE)?
Lixte Biotechnology Hldgs Inc (LIXT) has a return on equity of -62.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Lixte Biotechnology Hldgs Inc's operating cash flow?
Lixte Biotechnology Hldgs Inc (LIXT) recorded an outflow of $3.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Lixte Biotechnology Hldgs Inc's total assets?
Lixte Biotechnology Hldgs Inc (LIXT) had $12.7M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Lixte Biotechnology Hldgs Inc spend on research and development?
Lixte Biotechnology Hldgs Inc (LIXT) invested $255K in research and development during fiscal year 2025.
What is Lixte Biotechnology Hldgs Inc's current ratio?
Lixte Biotechnology Hldgs Inc (LIXT) had a current ratio of 3.88 as of fiscal year 2025, which is generally considered healthy.
What is Lixte Biotechnology Hldgs Inc's debt-to-equity ratio?
Lixte Biotechnology Hldgs Inc (LIXT) had a debt-to-equity ratio of 0.18 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Lixte Biotechnology Hldgs Inc's return on assets (ROA)?
Lixte Biotechnology Hldgs Inc (LIXT) had a return on assets of -47.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Lixte Biotechnology Hldgs Inc's cash runway?
Based on fiscal year 2025 data, Lixte Biotechnology Hldgs Inc (LIXT) had $5.1M in cash against an annual operating cash burn of $3.1M. This gives an estimated cash runway of approximately 20 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Lixte Biotechnology Hldgs Inc's Piotroski F-Score?
Lixte Biotechnology Hldgs Inc (LIXT) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Lixte Biotechnology Hldgs Inc's earnings high quality?
Lixte Biotechnology Hldgs Inc (LIXT) reported a net loss of $6.1M while operations used $3.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Lixte Biotechnology Hldgs Inc cover its interest payments?
Lixte Biotechnology Hldgs Inc (LIXT) reported an operating loss of $5.1M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.